Nonpres (Eplerenone)

Eplerenone, the active ingredient in Nonpres, is a mineralocorticoid receptor antagonist presented as an oral tablet for oral use. It is used to treat hypertension and heart failure in adult patients. GNH USA supplies Nonpres as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Eplerenone acts on the mineralocorticoid pathway to manage cardiovascular conditions. Hypertension: lowers blood pressure by reducing sodium and water retention. Heart failure: improves cardiac function and reduces the risk of hospitalization. Post‑myocardial infarction: helps prevent adverse remodeling and subsequent heart failure.

Eplerenone may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Hyperkalaemia: elevated serum potassium levels. - Dizziness or light‑headedness, especially on standing. - Headache. - Nausea or abdominal discomfort. - Diarrhoea. - Fatigue.

Serious or Rare Side Effects: - Severe hyperkalaemia leading to cardiac arrhythmia. - Acute renal failure or worsening renal function. - Anaphylactic or severe allergic reactions. - Hepatic dysfunction with elevated liver enzymes.

Before initiating therapy, clinicians should consider several safety measures. - Monitor potassium: check serum potassium regularly, especially after dose changes. - Assess renal function: evaluate creatinine and eGFR before and during treatment. - Use caution in patients with heart failure: adjust dose based on clinical response. - Avoid in severe renal impairment: contraindicated when eGFR is markedly reduced. - Pregnancy Category B: use only if the potential benefit justifies the potential risk. - Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Eplerenone can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Potassium supplements or salt substitutes: increase risk of hyperkalaemia. - ACE inhibitors or ARBs: additive effect on potassium levels. - NSAIDs: may impair renal function and raise potassium. - Cyclosporine: enhances potassium retention. - Trimethoprim‑sulfamethoxazole: potentiates hyperkalaemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may require potassium monitoring. - Digoxin: altered serum levels may occur. - Lithium: renal clearance may be reduced, increasing toxicity risk.